News and Announcements
Xeophin Pty Ltd announces the launch of it’s Pre ICO & ICO raise using Blockchain technologies in Europe and Asia
- Published June 26, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Xeophin, a biotech company, is committed to the research, development and commercialisation of new and novel medical treatments
- Have appointed Dr.Goran Ando as Chairman of its Clinical Advisory Committee
- Have appointed ex-Chairman of Novo Nordisk, Dr.Goran Ando, as Chairman of its Clinical Advisory Committee
Xeophin is focused on imunomodulating technologies and is committed to the research, development and commercialisation of new and novel medical treatments, in a number of high growth therapeutic areas such as inflammation.
Xeophin has also secured the appointment of Dr.Goran Ando as Chairman of its Clinical Advisory Committee.
Dr Ando has held the position of Chairman of Novo Nordisk A /S since 2013 and has been on the board since 2005, being re-elected several times throughout his tenure. Dr Ando is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. Dr Ando serves as chairman of the board of Symphogen A /S, Denmark and as a board member of Novo Holdings A /S, Denmark, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, and ICMEC, US. Dr Ando also serves as a Senior Advisor to Essex Woodlands Healthcare Partners, UK.
About Xeophin
Xeophin Pty Ltd is a Biotech Company with a focus on imunomodulating technologies, and is committed to the research, development and commercialisation of new and novel medical treatments, in a number of high growth therapeutic areas such as inflammation.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
